Acute Coronary Syndromes (ACS)

heartwire News

  • ACEP 2018 Hospital Reporting Unrelated to Better Patient Outcomes There is a broad consensus that measuring quality is important, but new emergency medicine data call some of these processes into question because they might not be improving patient care.
  • Bariatric Surgery Cuts CAD in Very Obese, but Do Effects Wane? Bariatric surgery reduces macrovascular disease in obese patients with diabetes. Although, weight regain remains a challenge in all patients, if expectations are realistic, it's a good treatment option.
  • Alert FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD, PAD The rivaroxaban/aspirin combination is for the prevention of thrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events.
  • Anticoagulants Linked to Reduced Dementia Risk in AF A new study suggests that dementia risk is increased and accelerated in seniors with atrial fibrillation, but treatment of AF with oral anticoagulants may reduce that risk.

Perspective

  • Requiem for Aspirin in Dual Antiplatelet Therapy?   Mounting evidence makes Dr Michelle O'Donoghue wonder whether the perennial question on the optimal duration of DAPT should be revised to: How soon can you drop the aspirin? Have you changed your practice?
  • TCT 2018 MitraClip for Secondary MR -- The Redux Two conflicting studies on the percutaneous treatment of secondary mitral regurgitation in patients with heart failure lead John Mandrola, MD, to compare and contrast as we await the tiebreaker third.
  • Beta-Blockade After MI: No Practice Should Be Set in Stone Meta-analyses suggest little benefit for beta-blockers in contemporary patients with normal ejection fraction after MI. What other dogma should be revisited in light of an evolving evidence base?
  • ESC 2018 Will GLOBAL LEADERS Change Dual Antiplatelet Therapy Regimens?   Drs Christopher Granger and Adnan Kastrati discuss the implications of the GLOBAL LEADERS trial comparing ticagrelor monotherapy with DAPT 1 year after stenting for acute or stable coronary disease.
www.pills24.com.ua

https://medicaments-24.com

www.steroid-pharm.com/nandrolone-phenylpropionate.html